- Home
- DOYU vs CADL Comparison
DOYU vs CADL Comparison
Compare DOYU & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOYU
- CADL
- Stock Information
- Founded
- DOYU 2014
- CADL 1999
- Country
- DOYU China
- CADL United States
- Employees
- DOYU N/A
- CADL N/A
- Industry
- DOYU Computer Software: Programming Data Processing
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- DOYU Technology
- CADL Health Care
- Exchange
- DOYU Nasdaq
- CADL Nasdaq
- Market Cap
- DOYU 246.3M
- CADL 278.6M
- IPO Year
- DOYU 2019
- CADL 2021
- Fundamental
- Price
- DOYU $8.28
- CADL $5.95
- Analyst Decision
- DOYU Hold
- CADL Strong Buy
- Analyst Count
- DOYU 1
- CADL 5
- Target Price
- DOYU $7.00
- CADL $21.40
- AVG Volume (30 Days)
- DOYU 78.3K
- CADL 627.9K
- Earning Date
- DOYU 08-18-2025
- CADL 08-14-2025
- Dividend Yield
- DOYU 238.73%
- CADL N/A
- EPS Growth
- DOYU N/A
- CADL N/A
- EPS
- DOYU N/A
- CADL N/A
- Revenue
- DOYU $586,290,301.00
- CADL N/A
- Revenue This Year
- DOYU N/A
- CADL N/A
- Revenue Next Year
- DOYU N/A
- CADL N/A
- P/E Ratio
- DOYU N/A
- CADL N/A
- Revenue Growth
- DOYU N/A
- CADL N/A
- 52 Week Low
- DOYU $5.68
- CADL $3.79
- 52 Week High
- DOYU $19.30
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- DOYU 57.64
- CADL 47.68
- Support Level
- DOYU $7.90
- CADL $5.45
- Resistance Level
- DOYU $8.59
- CADL $6.16
- Average True Range (ATR)
- DOYU 0.43
- CADL 0.32
- MACD
- DOYU 0.04
- CADL -0.07
- Stochastic Oscillator
- DOYU 76.43
- CADL 48.54
About DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.